Part D Helps Control Medicare Spending

05.06.13 | By

Last week the CMS Office of the Actuary, following legislatively proscribed duties, stated that actual and projected Medicare expenditures for 2011 through 2015 are low enough that they will not trigger the Independent Payment Advisory Board (IPAB) to recommend binding cuts to the Medicare program.

Medical Innovation Benefits Patient Health, Economic Growth

Remarks of Robert J. Hugin 
Pharmaceutical Research and Manufacturers of America
Wednesday, May 5, 2013 

Thank you all for joining me today.  I am Bob Hugin, Chairman of PhRMA and Chairman/ CEO of Celgene Corporation – a leading medical innovator whose objective to is to help patients with cancer and immune-related and inflammatory conditions live longer and better quality lives.

The Atlantic Live Event: How CBO Scoring Can Help Everyone’s Health

05.03.13 | By

Changes to Congressional Budget Office (CBO) scoring methodology always inspire a ripe discussion of policy.

New USTR Set to Play Critical Role in Growing U.S. Economy

05.02.13 | By

PhRMA would like to congratulate Michael Froman, who today was nominated by President Obama to be the new United States Trade Representative. This position is critically-important as our nation strives to improve its standing in the global marketplace and create new, high-paying jobs that will propel our economy in the 21st Century. His extensive experience working on important economic issues will certainly benefit our nation as we look toward a trade policy that will build a foundation for future prosperity.

Solving the Medication Adherence Challenge: Prescriptions for a Healthy America

05.02.13 | By

Not taking our medicines as prescribed is a serious problem and finding remedies to help patients stick with their treatments as directed would go a long way to better health, not to mention helping control healthcare costs.

Strong R&D Commitment to Mental Illness

05.02.13 | By

It was suggested yesterday that drug companies aren’t putting enough resources into developing medicines for mental illness.  This couldn’t be further from the truth.   The reality is that as an industry, we are deeply vested in finding new treatments for patients suffering from debilitating neurological and mental health illnesses. 

Small Business Summit Speaker Notes Vital Leadership Lessons

05.01.13 | By

I sat in on a few sessions at yesterday’s US Chamber of Commerce’s Small Business Summit, where I was lucky enough snag a front row seat (!) to hear General Michael Hayden give leadership advice to small businesses owners.

Castellani Talks Biopharma’s Future

04.29.13 | By

The question of the day is: what can we do to meet the enormous healthcare challenges ahead?  Truly, it’s the question of the decade.  The challenges are real.  The clock is ticking.  What we do today, tomorrow, next year and beyond to set sound policies in Washington, state capitals and around the world will mean the difference between solving problems and simply coping with the onslaught of disease.

Strong IP Encourages Innovation

04.29.13 | By

“A strong intellectual property rights system encourages investment by millions of people in the United States and abroad to engage in ongoing innovation. This is critical for future economic growth in the United States and elsewhere. America’s founding fathers considered this to be so important that they included the legal basis for our national patent and copyright system in the U.S.

New JAMA Study Highlights Continued Success of Medicare Part D

Washington, D.C. (July 27, 2011) — An important new study published today in the Journal of the American Medical Association found that the Part D prescription drug program saves Medicare about $1,200 per year in hospital, nursing home and other costs for each senior who previously lacked comprehensive prescription drug coverage.  According to other experts, this finding equals about $12 billion per year in savings across Medicare.


Subscribe to RSS - Opinion